Brief: United Laboratories International - Got Notice On Acceptance Of Clinical Trial From Nmpa Regarding Insulin Degludec And Insulin Aspart Injection.
26/04/2022 12:10
April 26 (Reuters) - United Laboratories International
Holdings Ltd 3933.HK :
* UNITED LABORATORIES INTERNATIONAL - GOT NOTICE ON
ACCEPTANCE OF
CLINICAL TRIAL FROM NMPA REGARDING INSULIN DEGLUDEC AND INSULIN
ASPART INJECTION.
Source text for Eikon: ID:nHKS9p5XrP
Further company coverage: 3933.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on United Laboratories International Holdings
See all newsBrief: United Laboratories International Receives Milestone Payment From Novo
Brief: United Laboratories International Says NMPA Accepts Insulin Degludec And Liraglutide Injection Marketing Registration Application
Brief: United Laboratories International Posts HY Profit Attributable RMB 347.6 Million
China's United Laboratories half-year profit drops 82%
Brief: United Laboratories International Expects HY Net Profit RMB 340 Million